The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
West-Nederland; Zuid-Holland; Agglomeratie Leiden en Bollenstreek
Location of affected unit(s)
Leiden
Sector
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21.10 - Manufacture of basic pharmaceutical products
New offshoring locations
United States, Japan
200 jobs Number of planned job losses
Announcement Date
2 June 2017
Employment effect (start)
Foreseen end date
Description
The Japan-owned Astellas Pharma announced in June 2017 that it will relocate its development and testing of medicines from Leiden, Zuid-Holland to Northbrook in the US and Tokyo in Japan, which will result in the loss of at the least 200 jobs in the Netherlands. The company has stated that Leiden will remain a regional centre that will undertake support activities, such as quality control, supply chain management and more.
As of June 2017, Astellas Pharma employs approximately 550 people in Leiden.
Sources
2 June 2017: Het Financieel Dagblad
Citation
Eurofound (2017), Astellas Pharma, Offshoring/Delocalisation in Netherlands, factsheet number 92903, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/92903.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
